| FENNEC PHARMACEUTICALS |
| Kanada |
| Gesundheit |
| CA31447P1009 / A12A5F |
| RV41 (Frankfurt) / FENC (NASDAQ) |
| FRA:RV41, ETR:RV41, RV41:GR, NASDAQ:FENC |
| - |
| https://fennecpharma.com/ |
|
Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing treatments that address ototoxicity, a form of hearing damage associated with certain cancer therapies. Its lead product, PEDMARK, is designed..
>Volltext.. |
| 315.54 Mio. EUR |
| 279.37 Mio. EUR |
| 52.87 Mio. EUR |
| -1.37 Mio. EUR |
| -3.22 Mio. EUR |
| -0.11 EUR |
| - |
| 36.82 Mio. EUR |
| -3.47 Mio. EUR |
| 3.33 |
| 83.42% |
| 68.11% |
| - |
| - |
| - |
| - |
| FENNEC |
| 27.10.26 |
|